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Background: Sepsis encompasses two phases, the ‘hyper’-reactive phase and the ‘hypo’-reactive phase.
The initial inﬂammatory stage is quickly counterbalanced by an anti-inﬂammatory response, which
compromises the immune system, leading to immune suppression. Regulatory T cells (Tregs) have been
implicated in the pathogenesis of sepsis by inducing immunosuppression; however, the role of CD39+
Tregs in the process of sepsis is uncertain. This study investigated the dynamic levels of CD39+ Tregs and
their phenotypic change in sepsis.
Methods: Fourteen patients with systemic inﬂammatory response syndrome (SIRS), 42 patients with
sepsis, and 14 healthy controls were enrolled. Sequential blood samples were used to analyze the
numbers of CD39+ Tregs and their phenotypic changes. Survival at 28 days was used to evaluate the
capacity of CD39+ Treg levels to predict mortality in sepsis patients.
Results: Sepsis patients displayed a high percentage (3.13%, 1.46%, and 0.35%, respectively) and mean
ﬂuorescence intensity (MFI) (59.65, 29.7, and 24.3, respectively) of CD39+ Tregs compared with SIRS
patients and healthy subjects. High-level expression of CD39+ Tregs was correlated with the severity of
sepsis, which was reﬂected by the sepsis-related organ failure assessment score (r = 0.322 and r = 0.31,
respectively). In addition, the expression of CD39+ Tregs was associated with survival of sepsis patients
(p < 0.01). By receiver-operating characteristic (ROC) curve analysis, the percentage and MFI of CD39+
Tregs showed similar sensitivities and speciﬁcities to predict mortality (74.2% and 85.1%, and 73.9% and
84.1%, respectively). Using Kaplan–Meier curves to assess the impact of CD39+ Tregs percentage and MFI
on overall survival, we found that a high CD39+ Tregs percentage (p < 0.001; >4.1%) and MFI (p < 0.001;
>49.2) were signiﬁcantly associated with mortality. Phenotypically, CD39+ Tregs from sepsis patients
showed high expression of CD38 and PD-1 (p < 0.01 and p < 0.01 respectively).
Conclusions: Increased expression of CD39+ Tregs was associated with a poor prognosis for sepsis
patients, which suggests that CD39+ Treg levels could be used as a biomarker to predict the outcome of
sepsis patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Sepsis, deﬁned as a systemic inﬂammatory response to
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).patients.1,2 Patients with sepsis often develop organ dysfunctions,
including tissue hypoperfusion and hypoxia, lactic acidosis,
oliguria, or altered cerebral function.3,4 In spite of extensive
research efforts over the last 20 years, sepsis remains the leading
cause of death in intensive care units (ICUs).5 As such, research into
the pathogenesis of sepsis would lead to a better understanding of
this complex syndrome and identify effective therapies.
There is a growing consensus that the initial inﬂammatory stage
is counterbalanced by an anti-inﬂammatory response after theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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pathogens or the development of a secondary infection in sepsis
patients.6 The subsequent immunosuppression might explain why
most of the clinical trials using anti-inﬂammatory strategies have
failed to improve the outcome of sepsis.7 This implies that rectifying
immunosuppression may be the key point for the treatment of
sepsis.8 It has long be recognized that CD4+CD25+ regulatory T
cells (Tregs) are important in maintaining self-tolerance and
regulating the immune response in both physiological and
pathological statuses.9,10 The population and function of Tregs are
considerably diverse, and phenotypically and functionally distinct
subsets of Tregs mediate immune suppression through distinct
mechanisms.11 CD39 is a useful marker for CD4+CD25+ Treg cells;
CD39-positive (CD39+) Treg cells have more signiﬁcant suppression
ability compared with CD39-negative (CD39) Treg cells.12 Of note,
an increase in CD39 expression on Tregs has been observed in
patients with HIV infection and is strongly associated with disease
progression.13Furthermore, an increase in CD39 expression on Tregs
has also been identiﬁed in tumors and autoimmune diseases.14
Although the critical role of CD39+ Tregs in some diseases has
been reported, the potential role of CD39+ Tregs in sepsis and its
connection with disease progression have not yet been elucidated.
Therefore, this study was designed to investigate the frequency of
CD39+ Tregs in sepsis and to determine whether the characteristics
of this subset are associated with disease severity and mortality.
2. Patients and methods
2.1. Patients and design
Healthy controls and patients with systemic inﬂammatory
response syndrome (SIRS) or sepsis were enrolled consecutively
from October 2012 to December 2013. The criteria for SIRS and
sepsis were those deﬁned by the American College of Chest
Physicians and the Society of Critical Care Medicine (ACCP/SCCM).15
In brief, a diagnosis of SIRS was deﬁned in the presence of two or
more of the following criteria: temperature <36 8C or >38 8C, heart
rate >90 beats per min in the absence of a pacemaker, respiratory
rate >20 times per min or PaCO2 less than 4.3 kPa (32 mmHg), and
white blood cell count >12  109/l or <4  109/l, or >10% immature
band forms. Sepsis was deﬁned as the presence of SIRS associated
with infection. Both SIRS and sepsis patients enrolled in this study
were patients admitted to the ICU for critical care. SIRS patients were
patients without any sign of infection on the ﬁrst day after elective
surgery. Exclusion criteria included age <18 years, pregnancy,
malignancy, HIV infection, presence of organ transplantation, and
immunosuppressive treatments; SIRS patients who developed
sepsis were also excluded during the follow-up period.
Upon admission to the ICU, the following data were recorded
for each patient: age, sex, severity of underlying medical
conditions, sepsis-related organ failure assessment (SOFA) score,
reasons for admission to the ICU, principal diagnosis, vital signs,
respiratory parameters, routine blood tests and microbiological
culture results. Survival or death was assessed during a follow-up
period of up to 28 days. Blood samples were obtained on day 0 from
all subjects, on day 5 from sepsis patients, and on the day that the
sepsis patients’ condition improved. Written informed consent
was obtained from the patients or their respective representatives.
The study was performed in accordance with the Declaration of
Helsinki and was approved by the Ethics Committee on Human
Research of Beijing 302 Hospital.
2.2. Flow cytometry analysis
Peripheral blood was collected in anticoagulant heparin-
containing tubes for ﬂow cytometry staining. In brief, antibodiesor isotype control antibodies were added to 100 ml whole blood in
the dark for 15 min at room temperature. After red blood cells were
lysed, cells were washed twice with phosphate-buffered saline
(PBS). The cells were then acquired and analyzed. CD4–ﬂuorescein
isothiocyanate (FITC) antibody and CD25–phycoerythrin (PE)
antibody were purchased from BD Pharmingen. CD127–Peridinin
chlorophyll protein (PerCP) antibody was purchased from BD
Bioscience. CD127–Brilliant violet 421 (BV421) antibody was
purchased from BioLegend. CD39–Allophycocyanine (APC) and
corresponding isotype control antibody were purchased from BD
Pharmingen. CD38–FITC and corresponding isotype control anti-
body were purchased from BD Pharmingen. programmed death 1
(PD-1) –FITC and corresponding isotype control antibody were
purchased from eBioscience. The corresponding isotype control
antibodies were used for gating the negative cells. All antibodies
were used according to the manufacturers’ recommended proto-
cols. FACSCalibur and CellQuest software were used to analyze the
results.
The lymphocyte population was gated based on morphological
parameters on a forward- versus side-scatter (FSC/SSC) plot. Tregs
were deﬁned as CD4+CD25+CD127 lymphocytes.16,17 The mean
ﬂuorescence intensity (MFI), which is commonly used to calculate
the expression levels of a molecule on cells, was calculated by
FACSCalibur and was used to present the expression levels of CD39
molecules on the membrane of Treg cells in this study.
2.3. Statistics
Data analyses were performed using SPSS version 13.0 software
(SPSS Inc., Chicago, IL, USA); data are expressed as the mean 
standard deviation. Statistical differences between two groups were
determined with the Mann–Whitney non-parametric U-test. The
comparison of data from the same individual was performed using
the Wilcoxon matched-pairs t-test. The statistical difference in
frequency distribution between groups was calculated using Pear-
son’s Chi-square test. Correlation analysis was evaluated by
Spearman rank correlation test. Kaplan–Meier curves were plotted
to display the impact on survival. Potential differences in overall
survival between groups were evaluated with log-rank tests.
Receiver-operating characteristic (ROC) curve analysis provided a
global and standardized appreciation of the accuracy of a marker for
predicting an event in the ICU during follow-up. This statistic allowed
a simple comparison of the accuracy of different prognostic scores
within the same population. A ROC curve represents the plot of
sensitivity against 1  speciﬁcity. Values of p < 0.05 were considered
signiﬁcant.
3. Results
3.1. Patient characteristics at baseline
The clinical characteristics of the subjects enrolled are shown in
Table 1. Fourteen patients with SIRS, 42 patients with sepsis, and
14 healthy subjects (controls), were enrolled in this study. Both
SIRS and sepsis patients were comparable in terms of gender and
age with the healthy control subjects (p = 0.92 and 0.15,
respectively). The SOFA score for sepsis patients was signiﬁcantly
higher than that for SIRS patients (p < 0.01). The most common site
of infection in sepsis patients was the lung (23 patients, 54.8%),
followed by abdomen (16 patients, 38.1%) and genitourinary tract
(three patients, 7.1%). Pathogen culture included Gram-negative
bacteria (21 patients, 50%), Gram-positive bacteria (nine patients,
21.4%), fungi (three patients, 7.1%), and negative culture (nine
patients, 21.4%). The mean ICU stay of sepsis patients was
22.4  8.6 days. The 28-day mortality rate of sepsis patients was
54.7%.
Table 1
Clinical characteristics of the subjects enrolleda
Healthy
controls
SIRS Sepsis p-Value
Number 14 14 42
Age, years 45.2  10.3 52.4  17.2 49.1  10.2 0.15
Sex, male/female 8/6 7/7 22/20 0.92
SOFA score - 4.6  2.1 10.9  4.4 <0.01
Site of infection
Lung - - 23 (54.8%) -
Abdomen - - 16 (38.1%) -
Urinary tract - - 3 (7.1%) -
Pathogen culture
Gram-negative
bacterial
- - 21 (50%) -
Gram-positive
bacterial
- - 9 (21.4%) -
Fungi - - 3 (7.1%) -
Negative culture - - 9 (21.4%) -
WBC, 109/l - 15.6  3.8 16.2  6.1 0.64
PCT, ng/ml - - 5.2  4.6 -
Mechanical
ventilation
- 3 (21.4%) 14 (33.3%) 0.61
Renal replacement
therapy
- 0 (0%) 10 (23.8%) 0.11
ICU stay, days - 2.9  0.9 22.4  8.6 <0.01
Mortality,
survival/
non-survival
- 0% (0/14) 54.7% (19/23) <0.01
SIRS, systemic inﬂammatory response syndrome; SOFA, sepsis-related organ failure
assessment; WBC, white blood cell count; PCT, procalcitonin.
a Data are shown as the number (%) or mean  standard deviation.
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severity of sepsis
We ﬁrst measured the quantity of CD39+ Tregs in the enrolled
subjects. The percentage of CD39+ Tregs at admission wasFigure 1. The expression of CD39+Tregs in sepsis patients. (A) The CD39+Tregs deﬁ
inﬂammatory response syndrome (SIRS) and sepsis patients. (B-C) The percentage and
subjects. Each circle represents an individual. ** P < 0.01.signiﬁcantly higher in sepsis and SIRS patients compared with
healthy control subjects (3.13%, 1.46%, and 0.35% respectively;
p < 0.01). In addition, sepsis patients displayed a higher percent-
age of CD39+ Tregs than SIRS patients (p < 0.01; Figure 1).
Further analysis indicated that the MFI of CD39+ Tregs was
lower in SIRS patients compared with that in sepsis patients
(29.7 and 59.65, respectively; p < 0.01). In the correlation analysis,
we found that the percentage and the MFI of CD39+ Tregs were
positively correlated with disease severity on day 0, which was
reﬂected by the SOFA score (r = 0.322 and r = 0.31, respectively). In
addition, CD39+ Treg levels on admission signiﬁcantly stratiﬁed
sepsis patients into survival and non-survival groups (p < 0.01;
Figure 2). We also found that the percentage of CD39+ Tregs in
infectious ascites (n = 14) was higher than that in peripheral blood
from patients with sepsis caused by an abdominal infection
(p < 0.05, Figure 3). In the follow-up study, sepsis patients (n = 13)
showed signiﬁcant decreases in CD39+ Treg levels (p < 0.01) as
they recovered from the disease (Figure 3).
The predictive accuracy value for 28-day mortality was
determined by ROC curve analysis. The area under curve (AUC)
was 0.85 (95% conﬁdence interval 0.67 to 0.94; p = 0.001) for the
percentage of CD39+ Tregs and 0.72 (95% conﬁdence interval
0.56 to 0.89; p = 0.012) for the MFI of CD39+ Tregs. The percentage
of CD39+ Tregs (cut-off point 4.1%) and the MFI of CD39+ Tregs
(cut-off point 49.2) showed similar sensitivity and speciﬁcity to
predict mortality (74.2% and 85.1%, and 73.9% and 84.1%,
respectively). Using Kaplan–Meier curves to assess the impact
of CD39+ Treg percentage and MFI on overall survival, we
found that a high percentage of CD39+ Tregs (p < 0.001; log
rank 14.05) and CD39+ Tregs MFI (p < 0.001; log rank 14.53)
were signiﬁcantly associated with mortality (Figure 4). These
data indicate that CD39+ Treg levels are signiﬁcantly increased
in sepsis; the increase is further associated with the severity of
sepsis.ned by CD4+CD25+CD127-CD39+ lymphocytes in healthy control (HC), systemic
 the mean ﬂuorescence intensity (MFI) of CD39+Tregs are shown in the enrolled
Figure 2. Increased CD39+Tregs expression is positively associated with the severity of sepsis. (A-B) The percentage and the mean ﬂuorescence intensity (MFI) of CD39+Tregs
are correlated with the SOFA score of septic patients. (C-D) The percentage and the mean ﬂuorescence intensity (MFI) of CD39+Tregs are associated with mortality of septic
patients. Each circle represents an individual.
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CD38 and PD-1 are usually used as phenotypic markers of Treg
cells. Thus, we further assessed the co-expression of CD39 and
these molecules on Treg cells in patients. In addition to the higher
expression of CD38 and PD-1 on CD39+ Tregs compared with
CD39 Tregs (data not show), the expression of these markers on
CD39+ Tregs was recorded in healthy, SIRS, and sepsis patients. As
shown in Figure 5, cell surface expressions of CD38 and PD-1 were
signiﬁcantly increased in sepsis patients compared with healthy
controls (p < 0.01 and p < 0.01, respectively). Meanwhile, cell
surface expressions of CD38 and PD-1 were different between
sepsis and SIRS (p < 0.01 and p < 0.01, respectively). These data
indicate that CD39+ Tregs in sepsis patients show a high level of
activation and are prone to exhaustion.Figure 3. Dynamic expression of CD39+Tregs in sepsis patients. (A) Differential expressio
infection. (B) The decreased CD39+Tregs level in blood correlates with improvement o4. Discussion
Sepsis is considered a race to the death between the pathogens
and the host immune system; maintaining a proper balance
between pro- and anti-inﬂammatory pathways determines the
fate of the sepsis patient. In addition to the overwhelming pro-
inﬂammatory immune response responsible for sepsis, sepsis
patients also appear to manifest rapid immune dysfunctions
consistent with a state of immune suppression. This state is
typically characterized by defects in both innate and adaptive
immune responses, and leads to secondary infection and increased
mortality.18,19 Tregs suppress both innate and adaptive immunity,
and are regarded as a marker of the prognosis or recurrence of the
underlying disease.20,21 Thus, measurement of the Tregs percent-
age might represent a simple and valuable surrogate marker ofn of CD39+Tregs in blood and ascites from patients with sepsis caused by abdominal
f septic patients. Each circle represents an individual. * P < 0.05; ** P < 0.01.
Figure 4. The CD39+Tregs level is a prognostic marker for sepsis patients. (A-B) Receiving operating characteristic (ROC) curve of CD39+Tregs as percentage of positive cells or
mean ﬂuorescence intensity (MFI) at day 0 for predicting mortality. Area under curve: 0.805 for CD39+Tregs percentage, and 0.728 for CD39+Tregs MFI. (C-D) Kaplan-Meier
survival curves of septic patients showing that septic patients with high CD39+Tregs level (>4.1%) and MFI (>49.2) have an increased mortality as compared to patients with
low CD39+Tregs level and MFI (P < 0.001 and P < 0.001 respectively). Follow-up period: 28 days.
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been identiﬁed, it appears that Tregs represent a double-edged
sword in infection; the role of Tregs in bacterial sepsis remains
controversial because of conﬂicting results in antibody-mediated
depletion experiments.22,23Figure 5. CD39+Tregs from septic patients express high levels of CD38 and PD-1. (A) Repre
Pooled data indicating that CD39+Tregs in septic patients express high levels of CD38 For sepsis patients, timely testing of the direction of the
inﬂammatory balance may be helpful to correct their immune
response. Meisel et al. reported that monocytic human leukocyte
antigen-DR (mHLA-DR)-guided granulocyte-macrophage colony-
stimulating factor (GM-CSF) therapy was helpful for restoringsentative dot plots showing the co-expression of CD39 and CD38, PD-1 on Tregs. (B)
and PD-1. * P < 0.05; **P < 0.01.
H. Huang et al. / International Journal of Infectious Diseases 30 (2015) 57–6362monocytic immunocompetence, reducing the duration of mechan-
ical ventilation and ICU stay for sepsis patients;24 this indicated
that biomarker-guided immunotherapy administered to sepsis
patients in the correct immune phase is a potential major advance
in the treatment of sepsis. Unfortunately, biomarkers that can be
used to identify those patients who are at the highest risk of
mortality and who thus might best beneﬁt from such therapies are
limited.
Recent studies showed that CD39+ Tregs constitute a special
subset of activated Tregs, possessing more powerful immune
suppression ability.25 However, the dynamics of CD39+ Tregs
expression and their association with the progression of sepsis
remain unknown. Our data provide evidence to support the
association between CD39+ Tregs and the progression of sepsis.
First, circulating levels of CD39+ Tregs increased signiﬁcantly in
sepsis patients compared with SIRS patients and healthy control
subjects. Second, there was a signiﬁcant positive correlation
between CD39+ Treg expression and the SOFA score. Furthermore,
ROC analyses indicated that the percentage or the MFI of CD39+
Tregs could serve as a biomarker for predicting the outcome of
sepsis (AUC 0.85 and 0.72, respectively). In contrast to our results,
recent work by Ku¨hlhorn et al. showed that the suppressive
capacity of FoxP3+ Tregs was not sufﬁcient to control overwhelm-
ing inﬂammation and early mortality, but was a prerequisite for
the recovery from severe sepsis.26 This suggests distinct pheno-
typic and functional subsets of Tregs mediate immune suppression
through distinct mechanisms.
It is established that CD39+ Tregs play a central role in inducing
immunosuppression;27 however, until now, very few studies have
investigated the phenotypic changes in CD39+ Tregs in patients
with sepsis. It has been demonstrated that CD39+ Tregs express
high levels of functional markers, including cytotoxic T lympho-
cyte-associated antigen-4 (CTLA-4), HLA-DR, and Ki-67, compared
with CD39 Tregs during hepatitis B virus infection.28 Further-
more, in autoimmune hepatitis, dysfunctional CD39+ Tregs were
found to correlate with aberrant control of Th17 cells.29 However,
Tregs are heterogeneous, and there is a discrepancy between their
physiology and the pathological condition. In this study, the
phenotype change of CD39+ Tregs was investigated in healthy
controls, SIRS, and sepsis patients. Our data show that sepsis
patients exhibit higher expression of functional markers such as
CD38 and PD-1, which may reﬂect that, in addition to the change in
the CD39+ Tregs population, the function of CD39+ Tregs is also re-
modiﬁed during sepsis. The increased expression of CD38 and PD-1
suggests that CD39+ Tregs are prone to activation and exhaustion.
This study is not without limitations. By ROC analyses, this
study indicates that CD39+ Tregs could serve as a biomarker for
predicting the mortality of sepsis patients; however more clinical
studies and additional animal studies are needed to elucidate the
associated mechanism. Further, although signiﬁcantly different
levels of CD39+ Tregs were found between blood and infectious
ascites, we did not compare the other sites of infection with blood
because of the limited samples, thus these data should be referred
to abdominal sepsis. Finally, we compared these ICU patients based
only on whether they were SIRS or sepsis patients because of the
relatively small sample size. If we increased the number of subjects
and stratiﬁed the data for different severities of disease such as
SIRS, sepsis, severe sepsis, and sepsis shock, the relationship of
CD39+ Treg expression with disease severity might be more
important.
In conclusion, our data show that sepsis is associated with a
profound dysfunction of CD39+ Tregs. The percentage and MFI of
CD39+ Tregs could serve as a biomarker for predicting the outcome
of sepsis. These data indicate that CD39+ Tregs may be a potential
target for rectifying the dysfunctional inﬂammatory response in
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